Introduction
Large-vessel vasculitis (LVV) typically involves the aorta and its major branches [1] . Giant cell arteritis (GCA) and Takayasu arteritis are the most common types of LVV [2, 3] . Nevertheless, non-infectious LVV may occur in the context of autoimmune and inflammatory diseases such as systemic lupus erythematosus, Sjögren's syndrome, rheumatoid arthritis, spondyloarthropaties, ulcerative colitis, sarcoidosis, other systemic vasculitis and polymyalgia rheumatica (PMR) [4, 5, 6] .
Patients with LVV often show non-specific clinical manifestations, including back or chest pain, malaise, weakness, weight loss, fever and increased levels of laboratory inflammatory parameters (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP] ). In some cases, structural imaging techniques may yield negative results in patients with early stages of the disease. In this context, a tool that may help us to make an early diagnosis of LVV could be of great relevance for clinicians. 18 F-FDG PET/CT was found to be of potential value to make an early diagnosis of large and medium vessels inflammation, even before the development of vascular structural changes [6] [7] [8] [9] [10] . It was also useful to establish the presence and extend of extracranial vasculitis in patients with GCA [7] [8] [9] [10] [11] . In this context, aortic involvement has been described in more than 50% of 18 F-FDG PET/CT scans performed in patients with GCA [7, 8, 12, 13] and a positive PET/CT has been associated with a significantly higher risk of complications such as aneurysms, stenosis and aortic dissection [14] . In these patients an early and adequate therapy (including glucocorticoids with/without immunosuppressive drugs) and close follow-up is important to prevent these severe complications [2, 3] .
Besides limitations for the early diagnosis of LVV, the structural imaging techniques have in some cases limitations in monitoring the vascular inflammatory activity. This fact highlights the need of a non-invasive sensitive tool for the follow-up of these patients in the clinical setting. In this context, the role of 18 F-FDG PET/CT has not been well established and, up to now, only a few studies involving a limited number of patients have been published with promising preliminary results [8, [15] [16] [17] [18] . A recent guideline recommended the use of 18 F-FDG PET/CT for the diagnosis of LVV. However, the authors of this guideline recognized that the utility of PET/CT in monitoring antiinflammatory therapy response is still unknown and requires further clarification [19] .
Taking all these considerations into account, the purpose of the present study was to evaluate the contribution of 18 F-FDG PET/CT in the follow-up of patients with LVV.
Methods

Patients
This study included 38 consecutive patients with LVV who were evaluated by 18 F-FDG PET/CT scan and showed abnormal 18 F-FDG uptake involving mainly the aorta. One patient was excluded due to technical problems and poor quality of PET/CT images. Therefore, we assessed 37 patients (28 women and 9 men, mean± standard deviation
[SD] age: 66.5±9.9 y.). Table 1 summarizes the main characteristics of the patients, including the features that led to perform PET/CT scan to determine the presence of LVV and the medical treatment at the time of the initial PET/CT.
All patients included in this study had an initial Twelve of the 37 patients had a previous diagnosis of typical "isolated" PMR, 3 atypical PMR, 6 GCA, 1 retroperitoneal fibrosis, 1 panuveitis, 1 rheumatoid arthritis, and 1 psoriatic arthritis. For the diagnosis of GCA and PMR the American College of Rheumatology classification criteria [20] , and the criteria proposed by Chuang et al [21] were used. Atypical PMR was defined when patients presented aches and pain resembling PMR and did not fulfill the quoted criteria. 18 F-FDG PET/CT scan was requested in patients with PMR, inflammatory arthritis and autoimmune diseases to determine the presence of LVV if they had persistent fever, inflammatory low back pain, diffuse lower limb pain, constitutional symptoms, lack of improvement with low-medium dose oral glucocorticoids and/or unexplained increase of ESR and CRP. In patients with GCA a PET/CT scan was performed to demonstrate extracranial involvement due to poor clinical response to glucocorticoids, unexplained low back, upper or lower limb pain, persistently increased ESR and CRP levels or relapses of the disease.
In the remaining 12 patients a PET/CT scan was performed because of the presence of non-specific symptoms, mainly fever, asthenia, weight loss. In these cases other conditions including autoimmune diseases and neoplasms had previously been excluded. In these 12 patients a diagnosis of "idiopathic" LVV vasculitis was made based on the PET/CT scan findings, the response to treatment and the clinical outcome over the extended follow-up.
Twenty-three out of the 37 patients (62.2%) were under long-term treatment The institutional review board has approved the study and all patients signed a written informed consent. For image evaluation, a semiquantitative analysis of 18 F-FDG uptake at the aortic wall was performed, calculating a target-to-background ratio (TBR) both for the initial and follow-up PET/CT scan. The TBR was obtained by dividing the aortic wall maximum standardized uptake value (SUVmax) by the blood pool SUVmax [22] . The entire aorta was checked and the area with the greatest intensity of uptake was considered for measuring the aortic wall SUVmax. CT images were carefully analyzed together with PET images in order to exclude the presence of atherosclerotic plaques that could show a focal FDG uptake. The initial and follow-up TBR and the clinical and biochemical outcome were compared.
Statistical analysis
All continuous data were expressed as mean± SD or median and IQR. The MannWhitney U test was applied to determine the significance of the differences (statistical significance was established at p values <0.05). All the calculations were performed using AnalystSoft Biostat Version 2009 for Windows (AnalystSoft Inc., Vancouver, Canada).
Results
Overall, the mean± SD TBR decreased significantly from 1.7±0.5 in the initial PET/CT scan to 1.5±0.3 in the PET/CT scan follow-up (p=0.0001). Twenty-one of the 37 patients evaluated (56.8%) experienced clinical improvement after the initial PET/CT scan and 16 patients (43.2%) had no clinical improvement. In the 21 patients with clinical improvement the mean TBR decreased significantly from 1.8±0.6 to 1.5±0.3 (p=0.0002). However, in the other 16 patients, in whom the treating physician considered that there was no clinical improvement following therapy, no statistically significant differences in TBR were found when data from the first and the follow-up PET/CT scans were compared (1.6±0.3 vs. 1.5±0.3, p=0.1416) ( Table 2 ).
In assessing inflammatory laboratory markers, the mean ESR was 40.3±35. when the first PET/CT scan was performed (1.8±0.7 to 1.4±0.3; p=0.0088) ( Table 3 ). As shown in 
Discussion
The role of 18 F-FDG PET/CT scan in early diagnosis of LVV, evaluation of the extent of the disease [7, 8, 13] and also in the management of these patients [10, 23] has previously been established. In this regard, in a former report we emphasized the potential value of the semiquantitative analysis of 18 F-FDG PET/CT images for the diagnosis of aortitis [11] .
In the present study, we assessed the results obtained of the semiquantitative analysis of aortic There are some methodological aspects that we followed at the time of performing 18 F-FDG PET/CT to assess imaging vascular inflammation in our patients with LVV. In this regard, in contrast to the 1-hour standard protocol applied in oncology, we feel that a delayed acquisition of images 2-3 hours after 18 F-FDG injection is more appropriate allowing better visualization of vessel wall uptake [26] [27] [28] . As described in the section of Methods, we followed this procedure in our assessment. Experts in the field have indicated that for PET/CT image evaluation qualitative methods is more specific than the semiquantitative ones but they have lower sensitivity [29] . Based on that and also in our own experience, we decided to apply in our study a semiquantitative analysis that allowed us the detection of subtle changes of 18 F-FDG uptake during the follow-up. In this context, it is mandatory that the acquisition and analysis of images may be rigorously carried out, using the same conditions for the initial and follow-up scan. All these factors were considered in our study and may contribute to a more accurate assessment of vascular inflammatory activity.
In our experience, a residual 18 F-FDG vascular uptake is very frequently observed, even in patients with clinical improvement. Thus, the follow-up mean TBR for patients with and without clinical improvement was higher than the cutoff of 1.34 established in a previous study including a control population [22] . This observation is in accordance with previous reports in which a persistent 18 F-FDG vascular uptake has been described, even up to 80% of cases at 6 months [30] . This uptake, even observed in asymptomatic patients with normal laboratory inflammatory parameters, has been attributed to persistent inflammatory activity, vessel wall remodeling or immune resistance and was not related to relapse [16, 30] . However, no studies have been conducted to analyze in depth this finding and the causes remain unclear.
Remarkably, we observed that the initial mean TBR was higher in patients who experienced clinical improvement following therapy when compared to the patients without clinical improvement although the difference was not significant. Based on this finding, we can hypothesize that a higher initial TBR, reflecting a more intense inflammatory process, seems to identify a subgroup of patients who may be more susceptible to reach clinical improvement following therapy. We acknowledge that this observation needs to be confirmed in larger series of patients.
There is still controversy on the routine monitoring and follow-up assessment of the patients by Our study has several limitations that should be considered. In most patients the follow-up PET/CT scan was requested due to a poor clinical outcome, which introduces a selection bias. In addition, baseline situation of the patients was very heterogeneous as more than sixty percent of our patients were already undergoing therapy when the first PET/CT scan was requested. With respect to this, the variability in the therapy and the different timing of follow-up PET/CT scans were also potential limitations. Nevertheless, we consider that our results reflect the real scenario in a clinical setting.
Conclusions
In conclusion, 18 * Based on the clinician judgment including information yielded in the PET/CT scan study.
